Neurosurgery

Science Corp Prepares First Brain Implant Trials with Reversible Neuron-Grown Interface

Max Hodak's $1.5B neurotech firm enlists Yale surgeon for 2027 human trials of biohybrid system that avoids tissue damage while commercializing vision-restoration device